Experienced in Small Lymphocytic Lymphoma (SLL)

Dr. Emily K. Curran

Hematology Oncology | Hematology | Oncology
University Of Cincinnati Physicians Company LLC
3130 Highland Ave, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Small Lymphocytic Lymphoma (SLL)
University Of Cincinnati Physicians Company LLC
3130 Highland Ave, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emily Curran is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Curran is rated as an Experienced provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Curran is currently accepting new patients.

Her clinical research consists of co-authoring 44 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Small Lymphocytic Lymphoma (SLL).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
University Of Cincinnati Medical Center, LLC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
3130 Highland Ave, Cincinnati, OH 45219

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate, Dexamethasone, Doxorubicin, Thioguanine
Study Phase: Phase 1
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: November 17, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: SEA-TGT, Pembrolizumab
Study Phase: Phase 1
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
View 8 Less Clinical Trials

44 Total Publications

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.
IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.
Journal: Haematologica
Published: July 24, 2025
Similar Doctors
Elite in Small Lymphocytic Lymphoma (SLL)
Dr. John C. Byrd
Hematology
Elite in Small Lymphocytic Lymphoma (SLL)
Dr. John C. Byrd
Hematology

University Of Cincinnati Physicians Company LLC

3130 Highland Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-584-4503
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Byrd is a Hematologist in Cincinnati, Ohio. Dr. Byrd is rated as an Elite provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Byrd is currently accepting new patients.

Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Suzanne M. Partridge
Hematology Oncology | Hematology | Oncology
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Suzanne M. Partridge
Hematology Oncology | Hematology | Oncology

Oncology Hematology Care Inc

3301 Mercy Health Blvd, Suite 100, 
Cincinnati, OH 
 (5.9 miles away)
513-751-2273
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Suzanne Partridge is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Partridge is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). Her top areas of expertise are Paget Disease of the Breast, Small Lymphocytic Lymphoma (SLL), Lung Cancer, Pleuropulmonary Blastoma, and Endoscopy. Dr. Partridge is currently accepting new patients.

Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Edward R. Broun
Hematology Oncology | Hematology | Oncology
Distinguished in Small Lymphocytic Lymphoma (SLL)
Dr. Edward R. Broun
Hematology Oncology | Hematology | Oncology

Oncology Hematology Care Inc

4777 E Galbraith Rd, Suite 1, 
Cincinnati, OH 
 (8.1 miles away)
513-751-2273
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Edward Broun is a Hematologist Oncology specialist and a Hematologist in Cincinnati, Ohio. Dr. Broun has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Small Lymphocytic Lymphoma (SLL). His top areas of expertise are Acute Myeloid Leukemia (AML), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Broun is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Curran's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile